Bristol-Myers Squibb Company (BMY) EV/Assets Ratio: 1.72x
Is Bristol-Myers Squibb Company’s EV/Assets ratio high or low?
Bristol-Myers Squibb Company's EV/Assets ratio of 1.72x is in line with its 5-year average of 1.64x, around the middle of its 5-year range (1.30x–2.10x).
The EV/Assets ratio for Bristol-Myers Squibb Company (BMY) is 1.72x as of Wednesday, June 10, 2026. It is above its 12-month average by 11.33% (1.55x).
BMY EV/Assets Ratio Chart
BMY Average EV/Assets Ratio Chart
BMY Current vs Average EV/Assets Ratio Chart
BMY EV/Assets Ratio Metrics
EV/ASSETS RATIO
1.72x
EV/ASSETS RATIO AVG TTM
1.55x
EV/ASSETS RATIO AVG 3Y
1.56x
EV/ASSETS RATIO AVG 5Y
1.64x
EV/ASSETS RATIO AVG 10Y
1.98x
EV/ASSETS RATIO AVG 15Y
2.16x
EV/ASSETS RATIO AVG 20Y
2.05x
CURRENT VS TTM AVG
+11.33%
CURRENT VS 3Y AVG
+10.33%
CURRENT VS 5Y AVG
+4.57%
CURRENT VS 10Y AVG
-13.29%
CURRENT VS 15Y AVG
-20.19%
CURRENT VS 20Y AVG
-16.28%
BMY Competitors' EV/Assets Ratio
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bristol-Myers Squibb Company (BMY) | $114.14B | 1.72x | 1.55x | 1.56x | 1.64x |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 4.10x | 4.45x | 4.69x | 4.46x |
| CVS Health Corporation (CVS) | $125.16B | 0.77x | 0.67x | 0.63x | 0.70x |
| Medtronic plc (MDT) | $103.04B | 1.42x | 1.59x | 1.53x | 1.60x |
| Danaher Corporation (DHR) | $130.25B | 1.72x | 1.98x | 2.16x | 2.26x |
| Elevance Health Inc. (ELV) | $87.43B | 0.88x | 0.80x | 1.03x | 1.13x |
| Pfizer Inc. (PFE) | $146.36B | 1.01x | 1.00x | 1.03x | 1.28x |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 7.30x | 8.88x | 9.09x | 8.50x |
| Cigna Corporation (CI) | $78.25B | 0.67x | 0.66x | 0.72x | 0.73x |
| Gilead Sciences, Inc. (GILD) | $151.21B | 2.97x | 3.05x | 2.44x | 2.15x |
Bristol-Myers Squibb Company EV/Assets Ratio Formula & Definition
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bristol-Myers Squibb Company EV/Assets Ratio FAQ
- What is the EV/Assets ratio for Bristol-Myers Squibb Company (BMY)?
- The EV/Assets ratio for BMY stock is 1.72x.
- Is Bristol-Myers Squibb Company's EV/Assets ratio high or low?
- Bristol-Myers Squibb Company's EV/Assets ratio of 1.72x is in line with its 5-year average of 1.64x, around the middle of its 5-year range (1.30x–2.10x).
- What is the TTM average EV/Assets ratio for Bristol-Myers Squibb Company (BMY)?
- The TTM average EV/Assets ratio for BMY stock is 1.55x.
- What is the 3Y average EV/Assets ratio for Bristol-Myers Squibb Company (BMY)?
- The 3Y average EV/Assets ratio for BMY stock is 1.56x.
- What is the 5Y average EV/Assets ratio for Bristol-Myers Squibb Company (BMY)?
- The 5Y average EV/Assets ratio for BMY stock is 1.64x.
- What is the 10Y average EV/Assets ratio for Bristol-Myers Squibb Company (BMY)?
- The 10Y average EV/Assets ratio for BMY stock is 1.98x.
- What is the 15Y average EV/Assets ratio for Bristol-Myers Squibb Company (BMY)?
- The 15Y average EV/Assets ratio for BMY stock is 2.16x.
- What is the 20Y average EV/Assets ratio for Bristol-Myers Squibb Company (BMY)?
- The 20Y average EV/Assets ratio for BMY stock is 2.05x.
Bristol-Myers Squibb Company EV/Assets Ratio History
| DATE | EV/ASSETS RATIO |
|---|---|
| 2026-06-10 | 1.72x |
| 2026-06-09 | 1.74x |
| 2026-06-08 | 1.72x |
| 2026-06-05 | 1.76x |
| 2026-06-04 | 1.74x |
| 2026-06-03 | 1.70x |
| 2026-06-02 | 1.69x |
| 2026-06-01 | 1.70x |
| 2026-05-29 | 1.75x |
| 2026-05-28 | 1.75x |
| 2026-05-27 | 1.76x |
| 2026-05-26 | 1.77x |
| 2026-05-22 | 1.81x |
| 2026-05-21 | 1.81x |
| 2026-05-20 | 1.79x |
| 2026-05-19 | 1.78x |
| 2026-05-18 | 1.76x |
| 2026-05-15 | 1.75x |
| 2026-05-14 | 1.74x |
| 2026-05-13 | 1.74x |
| 2026-05-12 | 1.74x |
| 2026-05-11 | 1.72x |
| 2026-05-08 | 1.73x |
| 2026-05-07 | 1.73x |
| 2026-05-06 | 1.74x |
| 2026-05-05 | 1.75x |
| 2026-05-04 | 1.76x |
| 2026-05-01 | 1.78x |
| 2026-04-30 | 1.84x |
| 2026-04-29 | 1.72x |
| 2026-04-28 | 1.73x |
| 2026-04-27 | 1.72x |
| 2026-04-24 | 1.74x |
| 2026-04-23 | 1.75x |
| 2026-04-22 | 1.74x |
| 2026-04-21 | 1.76x |
| 2026-04-20 | 1.75x |
| 2026-04-17 | 1.77x |
| 2026-04-16 | 1.75x |
| 2026-04-15 | 1.72x |
| 2026-04-14 | 1.73x |
| 2026-04-13 | 1.73x |
| 2026-04-10 | 1.74x |
| 2026-04-09 | 1.76x |
| 2026-04-08 | 1.75x |
| 2026-04-07 | 1.72x |
| 2026-04-06 | 1.76x |
| 2026-04-02 | 1.76x |
| 2026-04-01 | 1.81x |
| 2026-03-31 | 1.78x |
| 2026-03-30 | 1.76x |
| 2026-03-27 | 1.74x |
| 2026-03-26 | 1.76x |
| 2026-03-25 | 1.75x |
| 2026-03-24 | 1.71x |
| 2026-03-23 | 1.70x |
| 2026-03-20 | 1.71x |
| 2026-03-19 | 1.73x |
| 2026-03-18 | 1.76x |
| 2026-03-17 | 1.76x |
| 2026-03-16 | 1.76x |
| 2026-03-13 | 1.75x |
| 2026-03-12 | 1.75x |
| 2026-03-11 | 1.77x |
| 2026-03-10 | 1.77x |
| 2026-03-09 | 1.78x |
| 2026-03-06 | 1.78x |
| 2026-03-05 | 1.79x |
| 2026-03-04 | 1.82x |
| 2026-03-03 | 1.80x |
| 2026-03-02 | 1.82x |
| 2026-02-27 | 1.82x |
| 2026-02-26 | 1.80x |
| 2026-02-25 | 1.80x |
| 2026-02-24 | 1.81x |
| 2026-02-23 | 1.80x |
| 2026-02-20 | 1.79x |
| 2026-02-19 | 1.78x |
| 2026-02-18 | 1.76x |
| 2026-02-17 | 1.78x |
| 2026-02-13 | 1.79x |
| 2026-02-12 | 1.77x |
| 2026-02-11 | 1.77x |
| 2026-02-10 | 1.64x |
| 2026-02-09 | 1.64x |
| 2026-02-06 | 1.67x |
| 2026-02-05 | 1.62x |
| 2026-02-04 | 1.58x |
| 2026-02-03 | 1.54x |
| 2026-02-02 | 1.54x |
| 2026-01-30 | 1.52x |
| 2026-01-29 | 1.51x |
| 2026-01-28 | 1.51x |
| 2026-01-27 | 1.53x |
| 2026-01-26 | 1.51x |
| 2026-01-23 | 1.51x |
| 2026-01-22 | 1.52x |
| 2026-01-21 | 1.51x |
| 2026-01-20 | 1.50x |
| 2026-01-16 | 1.53x |
| 2026-01-15 | 1.56x |
| 2026-01-14 | 1.56x |
| 2026-01-13 | 1.54x |
| 2026-01-12 | 1.54x |
| 2026-01-09 | 1.54x |
| 2026-01-08 | 1.54x |
| 2026-01-07 | 1.56x |
| 2026-01-06 | 1.51x |
| 2026-01-05 | 1.48x |
| 2026-01-02 | 1.49x |
| 2025-12-31 | 1.50x |
| 2025-12-30 | 1.50x |
| 2025-12-29 | 1.50x |
| 2025-12-26 | 1.51x |
| 2025-12-24 | 1.52x |
| 2025-12-23 | 1.51x |
| 2025-12-22 | 1.51x |
| 2025-12-19 | 1.50x |
| 2025-12-18 | 1.49x |
| 2025-12-17 | 1.49x |
| 2025-12-16 | 1.51x |
| 2025-12-15 | 1.51x |
| 2025-12-12 | 1.47x |
| 2025-12-11 | 1.44x |
| 2025-12-10 | 1.44x |
| 2025-12-09 | 1.43x |
| 2025-12-08 | 1.45x |
| 2025-12-05 | 1.46x |
| 2025-12-04 | 1.46x |
| 2025-12-03 | 1.44x |
| 2025-12-02 | 1.38x |
| 2025-12-01 | 1.40x |
| 2025-11-28 | 1.40x |
| 2025-11-26 | 1.40x |
| 2025-11-25 | 1.40x |
| 2025-11-24 | 1.37x |
| 2025-11-21 | 1.34x |
| 2025-11-20 | 1.33x |
| 2025-11-19 | 1.33x |
| 2025-11-18 | 1.35x |
| 2025-11-17 | 1.35x |
| 2025-11-14 | 1.35x |
| 2025-11-13 | 1.39x |
| 2025-11-12 | 1.40x |
| 2025-11-11 | 1.39x |
| 2025-11-10 | 1.36x |
| 2025-11-07 | 1.35x |
| 2025-11-06 | 1.35x |
| 2025-11-05 | 1.34x |
| 2025-11-04 | 1.32x |
| 2025-11-03 | 1.33x |
| 2025-10-31 | 1.33x |
| 2025-10-30 | 1.32x |
| 2025-10-29 | 1.32x |
| 2025-10-28 | 1.33x |
| 2025-10-27 | 1.34x |
| 2025-10-24 | 1.35x |
| 2025-10-23 | 1.35x |
| 2025-10-22 | 1.36x |
| 2025-10-21 | 1.36x |
| 2025-10-20 | 1.34x |
| 2025-10-17 | 1.34x |
| 2025-10-16 | 1.34x |
| 2025-10-15 | 1.34x |
| 2025-10-14 | 1.35x |
| 2025-10-13 | 1.34x |
| 2025-10-10 | 1.35x |
| 2025-10-09 | 1.37x |
| 2025-10-08 | 1.36x |
| 2025-10-07 | 1.37x |
| 2025-10-06 | 1.38x |
| 2025-10-03 | 1.38x |
| 2025-10-02 | 1.39x |
| 2025-10-01 | 1.43x |
| 2025-09-30 | 1.38x |
| 2025-09-29 | 1.36x |
| 2025-09-26 | 1.35x |
| 2025-09-25 | 1.34x |
| 2025-09-24 | 1.36x |
| 2025-09-23 | 1.37x |
| 2025-09-22 | 1.37x |
| 2025-09-19 | 1.37x |
| 2025-09-18 | 1.39x |
| 2025-09-17 | 1.40x |
| 2025-09-16 | 1.40x |
| 2025-09-15 | 1.40x |
| 2025-09-12 | 1.40x |
| 2025-09-11 | 1.43x |
| 2025-09-10 | 1.42x |
| 2025-09-09 | 1.42x |
| 2025-09-08 | 1.41x |
| 2025-09-05 | 1.42x |
| 2025-09-04 | 1.41x |
| 2025-09-03 | 1.43x |
| 2025-09-02 | 1.43x |
| 2025-08-29 | 1.42x |
| 2025-08-28 | 1.41x |
| 2025-08-27 | 1.43x |
| 2025-08-26 | 1.42x |
| 2025-08-25 | 1.42x |
| 2025-08-22 | 1.44x |
| 2025-08-21 | 1.45x |
| 2025-08-20 | 1.44x |
| 2025-08-19 | 1.45x |
| 2025-08-18 | 1.44x |
| 2025-08-15 | 1.45x |
| 2025-08-14 | 1.43x |
| 2025-08-13 | 1.43x |
| 2025-08-12 | 1.41x |
| 2025-08-11 | 1.39x |
| 2025-08-08 | 1.39x |
| 2025-08-07 | 1.38x |
| 2025-08-06 | 1.37x |
| 2025-08-05 | 1.39x |
| 2025-08-04 | 1.38x |
| 2025-08-01 | 1.36x |
| 2025-07-31 | 1.34x |
| 2025-07-30 | 1.45x |
| 2025-07-29 | 1.47x |
| 2025-07-28 | 1.48x |
| 2025-07-25 | 1.50x |
| 2025-07-24 | 1.52x |
| 2025-07-23 | 1.52x |
| 2025-07-22 | 1.50x |
| 2025-07-21 | 1.47x |
| 2025-07-18 | 1.48x |
| 2025-07-17 | 1.50x |
| 2025-07-16 | 1.48x |
| 2025-07-15 | 1.46x |
| 2025-07-14 | 1.48x |
| 2025-07-11 | 1.47x |
| 2025-07-10 | 1.51x |
| 2025-07-09 | 1.49x |
| 2025-07-08 | 1.47x |
| 2025-07-07 | 1.46x |
| 2025-07-03 | 1.47x |
| 2025-07-02 | 1.49x |
| 2025-07-01 | 1.48x |
| 2025-06-30 | 1.46x |
| 2025-06-27 | 1.46x |
| 2025-06-26 | 1.46x |
| 2025-06-25 | 1.47x |
| 2025-06-24 | 1.47x |
| 2025-06-23 | 1.47x |
| 2025-06-20 | 1.47x |
| 2025-06-18 | 1.47x |
| 2025-06-17 | 1.48x |
| 2025-06-16 | 1.51x |
| 2025-06-13 | 1.53x |
| 2025-06-12 | 1.55x |
| 2025-06-11 | 1.54x |
| 2025-06-10 | 1.54x |
| 2025-06-09 | 1.52x |
| 2025-06-06 | 1.50x |
| 2025-06-05 | 1.49x |
| 2025-06-04 | 1.49x |
| 2025-06-03 | 1.50x |
| 2025-06-02 | 1.51x |
| 2025-05-30 | 1.50x |
| 2025-05-29 | 1.49x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner